40% reduction in pain scores (fibromyalgia/IBS patients) Pain threshold improved by 45 Neurotransmitter improvement (5-HT ↑28%, GABA ↑31%) Inflammation suppression (TNF-α ↓36%) Duration of efficacy ≥12 months (overall efficacy rate 90.9%). This evidence concerns the gene TNF and irritable bowel syndrome.